Crescent Biopharma, Inc. (NASDAQ:CBIO - Free Report) - Research analysts at Wedbush issued their Q2 2025 earnings estimates for Crescent Biopharma in a research report issued to clients and investors on Monday, July 14th. Wedbush analyst R. Driscoll anticipates that the biopharmaceutical company will post earnings of ($0.76) per share for the quarter. Wedbush currently has a "Outperform" rating and a $27.00 price target on the stock. The consensus estimate for Crescent Biopharma's current full-year earnings is ($0.16) per share. Wedbush also issued estimates for Crescent Biopharma's Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.30) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($2.96) EPS, FY2027 earnings at ($6.38) EPS, FY2028 earnings at ($4.54) EPS and FY2029 earnings at ($4.48) EPS.
Several other research analysts have also recently commented on the stock. Lifesci Capital upgraded shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 price target for the company in a report on Wednesday, June 18th. Wall Street Zen upgraded shares of Crescent Biopharma to a "sell" rating in a research report on Saturday, July 12th. TD Cowen upgraded shares of Crescent Biopharma to a "strong-buy" rating in a research report on Friday, June 20th. Finally, Stifel Nicolaus started coverage on shares of Crescent Biopharma in a research report on Wednesday, June 25th. They set a "buy" rating and a $28.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $25.67.
Read Our Latest Report on Crescent Biopharma
Crescent Biopharma Stock Up 2.5%
NASDAQ CBIO traded up $0.32 on Wednesday, hitting $13.34. 120,148 shares of the stock were exchanged, compared to its average volume of 118,489. Crescent Biopharma has a fifty-two week low of $11.06 and a fifty-two week high of $63.00. The stock has a market capitalization of $260.80 million, a PE ratio of -0.29 and a beta of 1.52.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Featured Articles
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
